258 results on '"Rijavec, E"'
Search Results
2. Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world scenario
3. Current Insights on the Treatment of Anaplastic Lymphoma Kinase-Positive Metastatic Non-Small Cell Lung Cancer: Focus on Brigatinib
4. Resistin is associated with overall survival in non-small cell lung cancer patients during nivolumab treatment
5. The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients
6. Erratum to ‘Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world scenario’: [ESMO Open Volume 7, Issue 2, April 2022, 100406](S2059702922000278)(10.1016/j.esmoop.2022.100406)
7. EP06.01-006 Multidisciplinary Team during the COVID-19 Pandemic: The BE-PACIFIC Italian Observational Study Analysis
8. Ramucirumab: preclinical research and clinical development
9. Erratum to ‘Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world scenario’
10. OA01.02 Impact of COVID-19 Outbreak on Lung Cancer Diagnosis and Continuum of Care: Data From an Italian Multicenter Study
11. Role of microRNAs in malignant mesothelioma
12. Sequential use of vinorelbine followed by gefitinib enhances the antitumor effect in NSCLC cell lines poorly responsive to reversible EGFR tyrosine kinase inhibitors
13. The immune metabolic prognostic index discloses the presence of radiological progression in patients with non-small cell lung cancer (NSCLC) treated with Nivolumab
14. P30.02 Assessing SIADH (Syndrome of Inapproriate Antidiuretic Hormone Secretion) Management and Outcome Among Lung Cancer Patients: The Assert Trial
15. Vitamin D plasma level can affect nivolumab drug exposure in a cohort of patients with non-small-cell lung cancer
16. CheckMate 817: First-Line Nivolumab plus Ipilimumab in Patients with ECOG PS 2 and Other Special Populations with Advanced NSCLC
17. 1318P Association between soluble PD-L1 and prognosis of non-small cell lung cancer (NSCLC) patients treated with immunotherapy
18. 1765P Developing a risk assessment score for cancer patients during the COVID-19 pandemic
19. 1277P An exosomal miRNA signature as predictor of benefit from immune checkpoint inhibitors in non-small cell lung cancer
20. 1689P The appropriateness of invasive ventilation in COVID-19 positive cancer patients: The hardest decision for oncologists
21. 1696P Incidence of influenza-like illness (ILI) in cancer patients during COVID-19: The ONCOVID prospective observational study
22. CheckMate 817 : nivolumab + ipilimumab en première ligne chez des patients atteints d’un cancer bronchique non à petites cellules (CBNPC) avancé avec un ECOG PS 2 et autres populations particulières
23. Incidence and clinical implications of late immune-related adverse events in long responders to PD-1/PD-L1 checkpoint inhibitors: A multicenter study
24. Nivolumab Plus Low-Dose IPILIMUMAB as First-Line Treatment of Advanced NSCLC: Overall Survival Analysis of Checkmate 817
25. ASSERT: A prospective, observational study measuring sodium improvement and outcomes in patients treated for moderate to severe hyponatremia secondary to syndrome of inappropriate antidiuretic hormone secretion (SIADH) in Italy (lung cancer cohort)
26. P1.01-59 Expanding Access to Large-Scale Genomic Mutational Analyses for Patients with Advanced NSCLC in Italy
27. P2.14-02 Interim Survival Analysis of Gefitinib Plus Vinorelbine in Advanced EGFR-Mutant Non-Small Cell Lung Cancer (Genoa Trial)
28. OA04.02 CheckMate 817: First-Line Nivolumab + Ipilimumab in Patients with ECOG PS 2 and Other Special Populations with Advanced NSCLC
29. Incidence of influenza-like illness (ILI) in cancer patients during COVID-19: The ONCOVID prospective observational study
30. P2.04-02 Predictive Value of Circulating Tumor Cells and Circulating Free DNA in NSCLC Patients Treated with Nivolumab
31. P1.04-15 Computerized Tomography Texture Analysis as Biomarker of Benefit from Nivolumab in Advanced Non-Small Cell Lung Cancer
32. P2.03-28 Whole Exome Sequencing to Discover Lung Tumor Predisposition in Women with Previous Breast Cancer
33. Lung cancer predisposition in women with previous breast cancer identified by whole exome sequencing
34. P1.07-023 The Correlation Between B7-H4 Expression and Survival of Non-Small Cell Lung Cancer Patients Treated with Nivolumab
35. MA 01.07 Lanreotide Maintenance in SCLC Expressing Somatostatine Receptors: Efficacy Results of Multicenter Randomized G04.2011 trial
36. Overall survival (OS) of selected patients (Pts) with non-small cell lung cancer (NSCLC) receiving nivolumab beyond progression
37. 92O - Nivolumab Plus Low-Dose IPILIMUMAB as First-Line Treatment of Advanced NSCLC: Overall Survival Analysis of Checkmate 817
38. 55P - Incidence and clinical implications of late immune-related adverse events in long responders to PD-1/PD-L1 checkpoint inhibitors: A multicenter study
39. 1828P - ASSERT: A prospective, observational study measuring sodium improvement and outcomes in patients treated for moderate to severe hyponatremia secondary to syndrome of inappropriate antidiuretic hormone secretion (SIADH) in Italy (lung cancer cohort)
40. Serum proteomic test in advanced non-squamous non-small cell lung cancer treated in first line with standard chemotherapy
41. Vinflunine for the treatment of non-small cell lung cancer
42. 1906P - Lung cancer predisposition in women with previous breast cancer identified by whole exome sequencing
43. Advances in treatment of mesothelioma
44. Correlation between circulating tumor biomarkers and positron-emission tomography in advanced non-small cell lung cancer
45. Clinical applications of a next-generation sequencing panel in non-small cell lung cancer
46. In vitro and in vivo antitumor efficacy of the sequentially combined vinorelbine and gefitinib in Non-Small Cell Lung Cancer cell lines
47. E24 - Overall survival (OS) of selected patients (Pts) with non-small cell lung cancer (NSCLC) receiving nivolumab beyond progression
48. 3123 Correlation between circulating tumor biomarkers and positronemission tomography in advanced non-small cell lung cancer
49. Serum proteomic test in advanced non-squamous non-small cell lung cancer treated in first line with standard chemotherapy.
50. Serum Mass-Spectrometry Test in First Line Advanced Nsclc Patients Treated with Standard Chemotherapy Regimens
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.